Amicus Therapeutics, Inc.
http://www.amicusrx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amicus Therapeutics, Inc.
Gene Therapies Dominate New Crop Of EU PRIME Recipients
Among the six new investigational products to make it onto the European Medicines Agency’s priority medicines scheme, five were gene therapies.
Sanofi Files New Pompe Hope Avalglucosidase Alfa In EU
The French drugmaker is looking to consolidate its dominance of the Pompe disease area by filing its successor to Myozyme in Europe, but Amicus Therapeutics' potential rival AT-GAA is on the horizon.
Finance Watch: One Week Of IPOs Total $818.2m
Relay raises $400m to kick off July’s second big week of US initial public offerings. Also, Ocumension and Immunotech launch Hong Kong IPOs, Amgen invests $421m in BeiGene’s $2.08bn offering, Cytokinetics gets up to $400m in deal and investment funding, and Imvax closes $111m series C round.
US FDA's Stein Outlines Functions Of Rare Disease, Inborn Error Groups In New OND Division
Office of New Drugs director Peter Stein shed some light on how the newly established Division of Rare Diseases and Medical Genetics will operate following the completion of the OND reorganization, drawing mixed reactions from industry speakers.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- ADMET
- Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Callidus Biopharma
- Celenex
- MiaMed, Inc.
- Scioderm, Inc.